2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 3000
No.13
“Comparative proteomic analysis of the liver in a murine model of non- alcoholic steatohepatitis” Third Department of Internal Medicine, Niigata University Medical School
No.12
“Inhibition of endoplasmic reticulum stress by 4-phenylbutyrate prevents steatohepatitis progression and tumorigenesis in NASH-HCC model mice” Department of Gastroenterology, Juntendo University School of Medicine
No.11
“Galectin-3 targeting drugs inhibit multiple pathological pathways leading to improvement of non-alcoholic steatohepatitis (NASH)” Galectin Therapeutics Inc.
No.10
AASLD 2012, “Hepatic gene expression of the SPTLC3 subunit of serine palmitoyltransferase is associated with the development of liver cancer in a NASH mouse model” Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medicine and Dental Sciencesq
No.9
2012, “Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)” Boehringer Ingelheim GmbH & Co. KG
No.8
“A Novel Murine Model Recapitulates the Pathogenesis of Human Non-alcoholic steatohepatitis (NASH) and NASH-related Hepatocellular Carcinoma”
No.7
“Effects of Telmisartan on a Murine Model of Non-alcoholic Steatohepatitis (NASH) and NASH-related Hepatocellular Carcinoma”
No.6
“The Chemical Chaperon 4-Phenylbutyrate Inhibits Liver Fibrosis and Tumorigenesis in High-Fat Diet With N-acetyl-β-D-glucosaminedase Inhibitor-Induced NASH Model Mice”Department of Gastroenterology, Juntendo University School of Medicine
No.5
“FXR agonists prevent steatosis, hepatocyte death and progression of NASH towards HCC in a hypoinsulinaemic mouse model of progressive liver disease” Phenex Pharmaceuticals AG